Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06956001RecruitingPhase 3
Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06962267RecruitingPhase 2
Study of TQB2916 with chemo for advanced pancreatic cancer
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT06962865RecruitingPhase 2
RC108 and Furmonertinib for first-line treatment of EGFR-mutated and MET-positive NSCLC
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
BeijingAges 18–75 - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07000253RecruitingPhase 2/Phase 3
Timing of local treatment for limited metastatic stomach or esophageal cancer
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
AmsterdamAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07005128RecruitingPhase 3
New Drug Combo for First-Line Extensive Small Cell Lung Cancer
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
Casa Grande, ArizonaAges 18–99 - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel for newly treated primary CNS lymphoma
This trial tests a new cancer immunotherapy called liso-cel (a CAR T-cell treatment) as a first treatment for people with primary CNS lymphoma who cannot have a stem cell transplant. If you've already received some high-dose methotrexate and your tumor responded, this study may offer a more targeted therapy to try to improve results.
Aurora, ColoradoAges 18 years+ - NCT07018037Recruiting
TTV levels during first immunotherapy for kidney cancer
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
Rome, RomeAges 18 years+ - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT07061535RecruitingPhase 2
Sintilimab, tafolecimab and chemo for advanced small cell lung cancer
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Changsha, HunanAges 18 years+ - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07109154Recruiting
Study of lung cancer treatment patterns in the real world
This study looks at the medical records of people with advanced non-small cell lung cancer to understand what treatments they received and whether those treatments follow official guidelines. It may help doctors learn how to improve care for future patients.
RecifeAges Any age - NCT07143045Recruiting
Zorifertinib for lung cancer that has spread to the brain
This trial tracks how well zorifertinib works as a first treatment for people with a specific type of advanced lung cancer that has spread to the brain or spinal cord lining. Participants may receive zorifertinib or another standard treatment, and researchers will monitor their response over time.
Hefei, AnhuiAges 18 years+ - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07183189RecruitingPhase 3
New drug combo vs standard for EGFR-mutated lung cancer
This trial tests whether adding a new targeted drug (SHR-A2009) to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. It's for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT07209059RecruitingPhase 2
Nivolumab plus first-line therapy for advanced Hodgkin lymphoma
This trial tests whether adding the immunotherapy drug nivolumab to the first treatment of advanced Hodgkin lymphoma can improve outcomes. It uses PET scans to guide therapy, potentially reducing the need for stronger chemotherapy.
MoscowAges 18–60 - NCT07221253RecruitingPhase 3
Study of Rilvegostomig or Durvalumab plus chemo for biliary tract cancer
This trial tests two immunotherapy drugs (rilvegostomig or durvalumab) combined with standard chemotherapy for people with bile duct or gallbladder cancer that has spread or cannot be removed. It aims to see if these combinations work better than chemo alone.
Birmingham, AlabamaAges 18 years+ - NCT07231445RecruitingPhase 1
ZG006 with immunotherapy for extensive small cell lung cancer
This trial tests a new drug, ZG006, combined with standard immunotherapy (PD-1/PD-L1 inhibitors) for people with advanced small cell lung cancer that hasn't been treated before. The goal is to find out if this combination works better than the current standard care.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 404 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.